Prokidney To Participate In Two Upcoming Conferences: Evercore Healthconx Conference And The Citi Global Healthcare Conference
Date
11/26/2024 7:31:31 AM
(MENAFN- GlobeNewsWire - Nasdaq) WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
Evercore HealthCONx conference
|
| Date: | December 3, 2024 |
| Time: | 8:45am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| | |
Citi Global Healthcare Conference
|
| Date: | December 4, 2024 |
| Format: | One-on-one meetings |
| | |
The live webcast for the Evercore fireside chat will be accessible through the“Events” section of the Investor Relations tab within ProKidney's website at . Investors interested in one-on-one meetings should contact their Evercore and/or Citi representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .
Investor Contacts:
ProKidney
Ethan Holdaway
...
LifeSci Advisors, LLC
Daniel Ferry
...
MENAFN26112024004107003653ID1108927375
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.